“Cognitive training” (CT) is a label used to describe paper-and-pencil or computerized exercises designed to engage a desired set of mental skills for the purpose of enhancing neurocognitive functioning. Although the literature on the topic is considerably rich (on PubMed, for the sole 2018, the use of “cognitive training” as title keyword returns 123 results), very few studies pose the fundamental question: “How does CT work?”, or, more precisely, “Based on which computational mechanisms would engaging in CT result into meaningful changes in outcome measures?”. The overwhelming majority of the studies focus on treatment efficacy by modelling outcome measures as a function of CT (e.g., an active CT condition versus an active control condition), but do not describe in detail the exact mechanistic reason why CT should have an effect in the first place (De Marco et al., 2014). Biological frameworks have been proposed [i.e., the hypothetical role played by neurotransfactors, synaptic connections and neuroplasticity (Castells-Sánchez et al., 2019)] but have not been introduced as an a posteriori interpretation, not as a driving principle for the design of the exercises.

From a merely clinical viewpoint, biological explanations are not necessarily of central importance. In fact, it is normal for clinicians and clinical researchers to prioritize benefits to patients over the mechanistic description of the instruments (once these have proven feasible, ethical and safe). After all, by the same logic, we still have not been able to clarify with rigorous detail by which exact biophysical mechanisms certain popular neuromodulation techniques operate, such as transcranial direct-current stimulation (Pelletier and Cicchetti, 2014).

Identifying the mechanisms CT might rely on is of particular importance for the treatment of neurodegenerative diseases. This is by no means a trivial issue. A condition like Alzheimer’s disease, for instance, is characterized by multiple pathophysiological mechanisms and it is against these that CT would have to be conceptualized. A prevalent hallmark in neurodegenerative diseases is the accumulation of abnormal protein forms and aggregates (Bayer, 2015). It is not simple to align the mechanisms of CT to these processes, as there is a fundamental theoretical distance between peptidic and behavioral variables preventing us from drawing direct causative links. Reflecting on this apparent theoretical incompatibility, however, can be a productive exercise. In fact, it enables us to define a common ground on which both cellular and peptidic as well as behavioral variables can be transposed and investigated. This is the level of the neural systems deputed to information processing, already identified by the Imaging Genetics framework as “a more proximate biological link to genes” and as “an obligatory intermediate of cognition, behavior and emergent phenomenon” (Mattay et al., 2008). It is at this level that CT can be devised as an instrument deputed to target a specific mechanism. The possibility of relying on cognitive operations to target the overall systems is also conveniently aligned with the use of neuroimaging as methodology to measure such systems. Techniques such as magnetic resonance imaging and positron emission tomography enable researchers to investigate properties of the brain throughout its entire topography. On this note, functional magnetic resonance imaging is particularly helpful because it allows the calculation of large-scale haemodynamic networks. This is particularly relevant for the study of neurodegeneration, because neurodegenerative diseases affect these networks with a large degree of selectivity (Seeley et al., 2009). As a result, focusing on whole-brain patterns of functional connectivity provides a theoretical ground on which disease mechanisms, training principles and test-retest outcome measurements are conveniently aligned (Figure 1).

Based on such alignment, we have proposed a CT hypothesis aimed at inducing synchronized activity of selected brain regions. Referring to Alzheimer’s disease as the diagnosis of interest, the underlying principle defining our hypothesis was that repeated task-related co-activation of multiple areas would result in increased resting-state functional connectivity among those areas (Martínez et al., 2013). On the basis that Alzheimer’s pathology selectively affects the brain’s default-mode network (Seeley et al., 2009; Pasquin et al., 2017), we designed a set of computerized exercises aimed at inducing co-activation of central hubs of this network. These exercises are centrally reliant on retrieval from semantic memory, but patients are also required to recruit a significant amount of executive resources in order to solve the tasks. The combined processing of semantic content, memory retrieval and executive control (each of which is supported by a specific theory-informed pattern of brain areas) is at the basis of the task-induced co-activation of multiple regions of the default-mode network including the hippocampus, lateral temporal cortex, posterior cingulate and medio-prefrontal cortex. After validating this principle in a cohort of healthy older adults (De Marco et al., 2016), we found that this approach up-regulates functional connectivity of the default-mode network in patients with mild cognitive impairment and a working diagnosis of prodromal Alzheimer’s disease (De Marco et al., 2018), in favor of our hypothesis. In further support of the construct validity of our CT conceptualization, we also found that the presence of a high load of white-matter hyperintensities (small lesions that impair inter-neuronal connectivity) is associated with significantly fewer modifications of network connectivity after CT (Bentham et al., 2019). To corroborate the efficacy of our network-based CT in a completely different diagnostic scenario in which, however, mild cognitive impairment has also been linked to disruption of functional connectivity in the default-mode network (Hou et al., 2016), we ran a pilot study in a group of 23 patients diagnosed with Parkinson’s disease (PD) and mild cognitive impairment, on the basis that up-regulation of the default-mode network would also translate into cognitive improvements in this diagnostic group. Twelve of these patients with a diagnosis of PD and mild cognitive impairment underwent the network-based CT as described in our previous studies with healthy older adult and prodromal Alzheimer’s disease participants (De Marco et al., 2016, 2018; Bentham et al., 2019). The remaining patients with PD and mild cognitive impairment acted as controls as they followed a pathway of care as usual. These two groups were compared on behavioral outcome measures only, with assessments at baseline, after four weeks and at a longer-term follow-up, 6 months after baseline.

In support of our hypothesis, after 4 weeks of CT, improvement from baseline was observed across most cognitive tests for the treatment group (Additional Figure 1). Significant changes that survived correction for multiple comparisons, however, were only detected for the Semantic Fluency test ($P = 0.001$), the Scales for Outcomes of PD–Cognition ($P = 0.002$) and the Trail Making test - part A ($P = 0.003$). In contrast, the participants in the control group showed no significant changes in any of the neuropsychological tests. The improvements observed in the PD treatment group just after termination of the training (at 4 weeks) were not maintained after 6 months, but their scores remained higher than those recorded at baseline, suggesting time limited benefit in the absence of sustained stimulation of target mechanisms. Interestingly, in this group no significant improvements in the reaction times or accuracy scores were found over the course of the CT sessions, suggesting that the observed improvements in the group receiving CT were not dependent on improved motor performance.

Aside from the small sample size that prevents definite and generalizable conclusions on the effectiveness of this CT for patients with PD and mild cognitive impairment, major limitations are identified:

---

**Perspective**

**Targeting mechanisms in cognitive training for neurodegenerative diseases**

Annalena Venneri*, Riccardo Manca, Linford Fernandes, Oliver Bandmann, Matteo De Marco
first, the absence of MRI data limits our margin of interpretation in this specific diagnostic sample; second, and more in general, concurrent neurovascular factors may impact on mechanisms and treatment response. On this note, the inclusion of multiple MRI sequences in future investigations may support a more robust interpretation of findings.

In conclusion, these findings corroborate the evidence that mechanistic CT aimed at inducing changes in functional connectivity of neural systems is effective in supporting performance gains in the presence of neurodegeneration. Central to this framework is the identification of treatment mechanisms. Our proposition is that a network-based approach is suitable for aligning disease pathology, treatment mechanisms, cognitive functioning and test-retest outcomes on the common theoretical ground of neural systems. We argue that the definition of such strong theoretical rationale confers considerable advantage in comparison to more pragmatic clinical studies that are solely interested in the effect of CT and often conceive CT as a simple “symptomatic” form of treatment (i.e., “memory difficulties, then memory exercises”). Non-pharmacological interventions can be a powerful instrument in the treatment of neurodegenerative diseases, yet are often tacitly regarded as subsidiary, auxiliary tools to be used alongside a main recognized form of treatment that usually consists of one or more medications. Pharmacological treatments are seen as the natural avenue to counteract cognitive decline in neurodegenerative diseases because they target disease mechanisms in a direct way, i.e., there is a direct causative link between the drug and the brain. In order to see CT approaches become a primary therapeutic option it is necessary to follow the same rationale and define CT approaches that address specific disease mechanisms either directly or indirectly. For this reason, we argue that a transition from a symptom-driven to a mechanism-driven approach to CT will enable this underdeveloped field of research to progress and become central for the development of treatment options against cognitive decline due to neurodegenerative diseases.

Annalena Venneri, Riccardo Manca, Linford Fernandes, Oliver Bandmann, Matteo De Marco

Department of Neuroscience, University of Sheffield, Sheffield, UK (Venneri A, Manca R, Bandmann O, De Marco M)
Department of Neurology, Leeds Teaching Hospitals NHS Trust, UK (Fernandes L)

*Correspondence to: Annalena Venneri, PhD, a.venneri@sheffield.ac.uk.
https://orcid.org/0000-0002-9488-2301 (Annalena Venneri)

Received: February 8, 2020
Peer review started: February 25, 2020
Accepted: May 6, 2020
Published online: September 22, 2020

https://doi.org/10.4103/1673-5374.299141

How to cite this article: Venneri A, Manca R, Fernandes L, Bandmann O, De Marco M (2021) Targeting mechanisms in cognitive training for neurodegenerative diseases. Neural Regen Res 16(3):500-501.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Open peer reviewers: Abraham M. Yakoub, Stanford University, USA; Bin Zhang, University of Pennsylvania, USA.

Additional files:
Additional file 1: Open peer review reports 1 and 2.
Additional Figure 1: Changes in cognitive performance in the treatment and control PD groups.

References
Bayer TA (2015) Proteiopathies, a core concept for understanding and ultimately treating degenerative disorders? Eur Neuropsychopharmacol 25:713-724.
Bentham C, De Marco M, Venneri A (2019) The modulatory effect of cerebrovascular burden in response to cognitive stimulation in healthy ageing and mild cognitive impairment. Neuro Plast 2019: 2305318.
Castells-Sánchez A, Roig-Colf F, Lamonja-Vicente N, Altes-Magnet M, Torán-Monterroja R, Via M, García-Molina A, Torns JM, Heras A, Alzamora MT, Forés R, Pera G, Dacosta-Aguayo R, Soriano-Ray J, Cáceres C, Montero-Alia P, Montero-Alia JJ, Jimenez-Gonzalez MM, Hernández-Pérez M, Perera A, et al. (2019) Effects and mechanisms of cognitive, aerobic exercise, and combined training on cognition, health, and brain outcomes in physically inactive older adults: The Projecte Moviment Protocol. Front Aging Neurosci 11:216.
De Marco M, Meneghelfo F, Duzzi D, Rigon J, Venneri A (2018) Up-regulation of DMN connectivity in mild cognitive impairment via network-based cognitive training. Curr Alzheimer Res 15:578-589.
De Marco M, Shanks MF, Venneri A (2014) Cognitive stimulation: the evidence base for its application in neurodegenerative disease. Curr Alzheimer Res 11:469-483.
Hou Y, Yang J, Lue C, Song W, Ou R, Liu W, Gong Q, Shang H (2016) Dysfunction of the default mode network in drug-naive Parkinson’s disease with mild cognitive impairments: A resting-state fMRI study. Front Aging Neurosci 8:247.
Martínez K, Solana AB, Burgaleta M, Hernández-Tamames JA, Álvarez-Linera J, Román FJ, Alfayate E, Priado J, Escorial S, Quiroga MA, Karama S, Bellec P, Colom R (2013) Changes in resting-state functionally connected parietofrontal networks after videogame practice. Hum Brain Mapp 34:3143-3157.
Mattek VS, Goldberg TE, Sambataro F, Weinberger DR (2008) Neurobiology of cognitive aging: Insights from imaging genetics. Biol Psychol 79:9-22.
Passquini L, Benson G, Grothe MJ, Utz L, Myers NE, Yakushev I, Grimmner T, Schier M, Song C, Alzheimer’s Disease Neuroimaging Initiative (2017) Individual correspondence of Amyloid-β and intrinsic connectivity in the posterior default mode network across stages of Alzheimer’s disease. J Alzheimers Dis 58:763-773.
Pellegrini SI, Cicchetti F (2014) Cellular and molecular mechanisms of action of transcranial direct current stimulation: evidence from in vitro and in vivo models. Int J Neuropsychopharmacol doi: 10.1039/jijnpsyu0047.
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD (2009) Neurodegenerative diseases target large-scale human brain networks. Neuro 62:42-52.
P-Reviewers: Yakoub AM, Zhang B; C-Editors: Zhao M, Li HY; T-Editor: Jia Y
Additional Figure 1 Changes in cognitive performance treatment and control PD groups

Mean cognitive scores (95% CI) at baseline, 4 weeks and 6 months in 23 patients with Parkinson’s disease with mild cognitive impairment allocated to two groups: treatment (n = 12), those who underwent CT, and control (n = 11), those who did not undergo CT. Significant ANOVA results (*P < 0.05, **P < 0.00625) are shown for the comparisons between scores at baseline, at 4 week- and at 6 month- follow-ups. MMSE: Mini Mental State Examination, SCOPA-COG: Scales for Outcomes of PD – Cognition, TMT-A/B: Trail Making test – part A and B.

Candidate participants with a working diagnosis of PD were recruited from the movement disorder clinic at the Royal Hallamshire Hospital, Sheffield, UK. All participants fulfilled PD Society Brain Bank Criteria, were on stable treatment regime, reported subjective cognitive impairment and had a Mini Mental State Examination score between 23 and 27. Exclusion criteria consisted of the presence of concomitant diagnostic elements other than a diagnosis of PD that could have otherwise accounted for the presence of neurological symptoms. The study received ethical approval from the Regional Ethics Committee of Yorkshire and Humber (Ref No: 12/YH/0474). All participants provided written informed consent. All study procedures were carried out in compliance with the 1964 Declaration of Helsinki and its subsequent amendments. At baseline, participants underwent a comprehensive cognitive assessment in line with the Movement Disorder Society Task Force recommendations. The threshold of statistical significance was set at 0.05 and the Bonferroni correction was used to account for multiple comparisons (P = 0.05/8 = 0.00625). The two groups (CT and control condition, respectively) did not differ in age (73.0 ± 7.68 vs. 75.7 ± 4.73), years of education (18.5 ± 3.09 vs. 17.7 ± 3.13), years of disease duration 11.1 ± 3.34 vs. 12.3 ± 6.12), MMSE (25 ± 1.85 vs. 25 ± 1.56) and SCOPA-COG (25 ± 4.45 vs. 23 ± 4.58). All showed objective mild cognitive impairment when tested with neuropsychological assessment.